Core Insights - Integra LifeSciences reported revenue of $402.06 million for Q3 2025, a year-over-year increase of 5.6% and an EPS of $0.54 compared to $0.41 a year ago, indicating positive growth in earnings [1] - The reported revenue fell short of the Zacks Consensus Estimate of $414.8 million, resulting in a surprise of -3.07%, while the EPS exceeded expectations by +25.58% [1] Revenue Breakdown - Organic revenue growth was reported at 5%, below the four-analyst average estimate of 8.5% [4] - Codman Specialty Surgical revenue totaled $292.58 million, compared to the estimated $300.46 million, reflecting an 8.1% year-over-year increase [4] - Tissue Technologies revenue was $109.48 million, below the estimated $114.4 million, showing a slight decline of -0.5% year-over-year [4] - Within Tissue Technologies, Wound Reconstruction and Care generated $83.99 million, slightly below the $84.83 million estimate, marking a +4.4% year-over-year change [4] - Private Label revenue was reported at $25.49 million, significantly lower than the $29.58 million estimate, representing a -13.9% year-over-year decline [4] Stock Performance - Shares of Integra have returned +4.8% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Integra LifeSciences reported revenue of $415.61 million for the quarter ended June 2025, reflecting a year-over-year decline of 0.6% and an EPS of $0.45 compared to $0.63 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $395.64 million by 5.05%, and the EPS also surpassed the consensus estimate of $0.43 by 4.65% [1] Revenue Performance - Organic Revenue Growth was -1.4%, better than the average estimate of -6.3% based on four analysts [4] - Codman Specialty Surgical revenue totaled $303.96 million, exceeding the average estimate of $294.18 million by four analysts, representing a year-over-year change of +0.7% [4] - Tissue Technologies revenue was $111.65 million, compared to the estimated $101.48 million, showing a year-over-year decline of -4.1% [4] - Wound Reconstruction and Care revenue within Tissue Technologies was $84.75 million, surpassing the average estimate of $80.24 million, with a year-over-year change of -3.4% [4] - Private Label revenue in Tissue Technologies was $26.9 million, exceeding the two-analyst average estimate of $25.3 million, reflecting a year-over-year decline of -6.3% [4] Stock Performance - Shares of Integra have returned -8.5% over the past month, contrasting with the Zacks S&P 500 composite's +2.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]